A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
An Open-label, Phase I Dose Escalation and Expansion Trial to Investigate Safety and Efficacy of BI 1821736 in Patients With Advanced Solid Tumors
Sponsor: Boehringer Ingelheim
Terminated
Sponsor decision
Other terminated trials from Boehringer Ingelheim
A PHASE1 clinical study on Solid Tumors, this trial is terminated or withdrawn. The trial is conducted by Boehringer Ingelheim and has accumulated 15 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Aug 2025 — Present [monthly]
Terminated PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Terminated PHASE1
-
May 2025 — Jun 2025 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Jan 2025 — May 2025 [monthly]
Suspended PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Suspended PHASE1
▶ Show 10 earlier versions
-
Oct 2024 — Dec 2024 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Aug 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .